Larimar Therapeutics (LRMR) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 166.0% versus a loss of 41.7%. Over five years, PRLD leads with a -76.4% price change compared with -77.3% for LRMR. Prelude Therapeutics is the larger company by market cap ($305.6 million vs $285.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | PRLD |
|---|---|---|
| Share price | $2.75 | $3.83 |
| Market cap | $285.68M | $305.65M |
| 1-day change | -1.08% | +0.52% |
| YTD return | -27.82% | +32.07% |
| 1-year return | -41.74% | +165.97% |
| 5-year return | -77.31% | -76.45% |
| EPS (TTM) | $-1.99 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $6.83 |
| 52-week low | $2.72 | $1.15 |
| Distance from 52-week high | -57.17% | -43.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +423.64% | +140.21% |
| Average volume | 1.32M | 477.81K |
| Shares outstanding | 103.88M | 65.08M |
| Employees | 71 | 79 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed LRMR by 207.7 percentage points over the past year.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
LRMR vs PRLD FAQ
Which is bigger, Larimar Therapeutics or Prelude Therapeutics?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $305.65M compared with $285.68M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, LRMR or PRLD?
PRLD returned +165.97% over the past 12 months, compared with -41.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Larimar Therapeutics and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.